Clinical trial
A Phase I Dose Escalation of ZD1839 (Iressa®) (Days 1 and 2) and Docetaxel (Day 3) Every 3 Weeks in Patients With an Advanced Solid Tumor
NCT00084786 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Dose Escalation of ZD1839 (Iressa®) (Days 1 and 2) and Docetaxel (Day 3) Every 3 Weeks in Patients With an Advanced Solid Tumor
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 31, 2004
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
unspecified adult solid tumor, protocol specific